Q&A with Dr. Chandra Bhattacharya: Designing a Novel Platform to Improve CAR T Cell Therapy
October 9, 2024Chandrabali Bhattacharya, PhD, of the University of Nevada, Las Vegas, is developing a platform for in vivo CAR T cell therapy, which could have a tremendous impact on the field of cancer immunotherapy.
Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that has shown great success against treatment-resistant acute lymphoblastic leukemia, a type of aggressive blood cancer common in children.
However, CAR T cell therapy is a complex and very expensive process. It involves extracting the patient’s T cells, modifying them in a lab so they can detect and kill the cancer, and then reinjecting them into the patient.
Chandrabali Bhattacharya, PhD, an assistant professor at the University of Nevada, Las Vegas, received a 2024 PhRMA Foundation Faculty Starter Grant in Drug Delivery for her work to develop a platform for in vivo CAR T cell therapy, in which the modification of the T cells happens inside the body. If successful, this technology could have a tremendous impact on the field of immunotherapy by making CAR T cell therapy more efficient and more accessible to patients.
Watch this video to learn about Bhattacharya and her research.
Learn more about the PhRMA Foundation’s fellowship and grant opportunities. Check out more researcher stories on our blog.
